A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother transferred through placenta safeguard newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination during third trimester still offers significant protection for infants
Strong evidence from current research
The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study undertaken in England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing strong and reliable data of the vaccine’s real-world impact. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research provides healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured real-world outcomes rather than experimental conditions, providing real-world data of how the vaccine functions when given across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its risks
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents frequently observe their babies visibly struggling, their chests heaving as they attempt to draw sufficient oxygen into their damaged lungs. Whilst the majority of babies improve through palliative treatment, a modest yet notable proportion perish from RSV-related complications yearly, making immunisation programmes a essential public health imperative for defending the youngest and most at-risk people in our communities.
- RSV causes inflammation in lungs, causing severe breathing difficulties in infants
- Approximately half of infants contract the infection during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies die from RSV related complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the significance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides nearly 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.
The communication from health authorities stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the national data shows consistently strong protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to connect with women during pregnancy
- Geographic variations in immunisation take-up in different parts of England demand focused enhancement
- Regional health providers adapting programmes to suit specific population needs
Practical implications and parental perspectives
The vaccine’s impressive effectiveness provides real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the rollout of this preventative solution, the 80% drop in admissions equates to thousands of infants spared from severe infection. Parents no longer face the distressing scenario of seeing their babies gasping for air or difficulty feeding, symptoms that mark critical RSV illness. The vaccine has substantially transformed the picture of neonatal breathing health, offering expectant mothers a proactive tool to safeguard their most vulnerable children during those critical early months.
For families like that of Malachi, whose severe RSV infection resulted in severe brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women navigating their late pregnancy, converting what was once an unavoidable seasonal threat into a manageable health risk.